How could UnitedHealth's challenge to Medicare Advantage star ratings affect Humana?
Regulatory uncertainty over MA star ratings may alter Humana's competitive position UnitedHealth Group is suing the Centers for Medicare & Medicaid Services (CMS) over its 2027 Medicare Advantage star ratings, challenging the agency's use of 26 measures across 45 contracts. This legal action introduces significant regulatory uncertainty into the Medicare Advantage market. If the rating methodology is altered or if CMS softens its audit crackdown, it could change how plans are perceived by patients and how government bonus payments are distributed.
- Effect
- Mild negative
- How direct
- 2 steps, 1 inferred by Brind
- When
- Within months
- The story
- Still developing
How it reaches Humana
-
UnitedHealth Group filed a lawsuit against the Centers for Medicare & Medicaid Services in federal court in Brunswick, Georgia, on November 19, 2026, challenging its 2027 Medicare Advantage star ratings. UnitedHealth alleges that CMS improperly used 26 measures to rate 45 of its contracts, claiming the agency either lacked legal authority or failed to provide an objection period. The company states that if CMS calculated the ratings correctly, those contracts would score at least half a star and up to 1.5 stars higher.
The full event1independent outlet -
UnitedHealth Group sued the Centers for Medicare & Medicaid Services (CMS) in federal court, challenging the agency's use of 26 measures to rate 45 of its contracts for 2027. UnitedHealth claims the agency either lacked legal authority or failed to give the company a chance to object.
1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- 247wallst.com Yesterday
-
International law firm
Everything about CMS -
The lawsuit and the concurrent consideration of a CMS audit crackdown create uncertainty regarding the stability of the rating system. Since star ratings are the government’s “principal signal” to patients and determine bonus payments, any change in this system affects the competitive environment for all major plans, including Humana.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
American managed health care company
Everything about Humana
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- UnitedHealth Group sued CMS over its 2027 Medicare Advantage star ratings.247wallst.com
- The suit challenges CMS's use of 26 measures to rate 45 of UnitedHealth's contracts.247wallst.com
- Contracts with at least four stars earn government bonus payments.247wallst.com
- Low ratings could cut benefits and raise premiums for patients.247wallst.com
Why it matters
The Medicare Advantage market is highly competitive, and star ratings are critical determinants of success. These ratings not only influence patient enrollment—as low ratings make it harder to keep members—but they also unlock substantial government bonus payments. For Humana, like other major managed care providers, the stability and fairness of the rating system are fundamental to its revenue and market standing.
This legal fight is part of a broader regulatory tension between large providers and CMS. UnitedHealth is not the only entity involved; CVS Health is also suing CMS over the 2027 ratings. The outcome of this legal battle could set a precedent for how all major players in the Medicare Advantage space operate and compete.
What we don't know yet
- Will CMS agree to recalculate the ratings, or will the dispute proceed through the courts?
- How will CMS respond to the lawsuit while simultaneously considering an audit crackdown?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- 247wallst.comYesterday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.